$SBEV

SPLASH BEVERAGE GROUP, INC. (SBEV): Entry into a Material Definitive Agreement

SPLASH BEVERAGE GROUP, INC. (SBEV) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001553788 0001553788 2026-07-15 2026-07-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Repor

Original reporting
Published Jul 21, 2026, 8:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 8:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$SBEV
Neutral
medium confidence
Mentioned
$SBEV
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SBEVNeutralMed
01

Why it matters

The amendment extends the remaining unpaid settlement payments into a new July 31, 2026 due date and specifies 12% annual interest plus reasonable attorney’s fees, changing the company’s near-term cash flow profile and legal-cost expectations.

02

Market read

This filing provides a concrete, date-specific settlement cash obligation and cost terms that can influence liquidity and risk pricing for SBEV.

03

What to watch

Traders may be underweighting the 12% per annum interest and attorney-fee obligations, which can compound if any further payment disputes arise.

Relevance 6/10Novelty 6/10Timing: after-hours filing, with the next cash obligation due July 31, 2026

Background

The company previously agreed to installment settlement payments to three investors over alleged October 2024 breach claims, with installments due by June 30 and July 15, 2026.

Company-level read

Ticker impact

$SBEVNeutralMedium confidence
Context

Splash Beverage Group entered amendments extending settlement payments, setting $137,797.54 due July 31, 2026 plus 12% interest and attorney fees.

Expected impact

Near-term downside risk is limited by the July 15 payment already made, but the July 31 remaining payment plus 12% interest can keep credit/liquidity concerns elevated.

Evidence & confidence

This is a primary-source legal/settlement modification with specific amounts, dates, and interest terms, which can affect perceived liquidity and risk premium even without a new operating catalyst.

Market effects

Limited sector read-across; this is company-specific settlement administration rather than an industry-wide regulatory or demand signal.

No clear regional market linkage beyond microcap liquidity sentiment.

No material global relevance indicated.

Counterpoint

The amendment may be viewed as a negotiated de-risking versus a harsher default scenario, with the July 15 tranche already paid.

Key entities

  • Splash Beverage Group, Inc.

    Entered amendments to settlement agreements with three prior investors, extending remaining payment timing and adding 12% interest and attorney’s fees.

  • Three prior investors

    Parties to the amended settlement agreements; receive remaining unpaid settlement payments on July 31, 2026.

Related articles

$SBEVMed

Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours Splash Bev

Splash Beverage Group Inc. (NYSE:SBEV) shares are trending on Friday. Shares of the Florida-based company climbed 64.10% to $0.57 after the bell on Thursday. The surge in the late trading session follows an intraday gain of 7.07% which closed the SBEV at $0.35, according to Benzinga Pro data. Splash Beverage Group, which engages in the manufacturing, distribution, marketing, and sale of various beverages, experienced an exceptionally elevated trading session on Thursday.

$SBEVMed

Splash Beverage Group Expands CannEpil Platform into Veterinary Therapeutics, Establishing Second FDA-Regulated Pharmaceutical Development Program

Splash Beverage Group (NYSE American: SBEV) said it expanded its exclusive global CannEpil license to cover veterinary therapeutics. The company plans initial evaluation for companion-animal oncology and chronic pain, pursuing FDA Center for Veterinary Medicine INAD and Conditional Approval pathways. Splash will pay Argent BioPharma a 10% royalty on veterinary net revenues.

$SBEVMedAI 8/10

Splash Beverage Group Announces Significant Balance Sheet Improvement and Board Approval of Reverse Stock Split as Company Continues Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said it settled legacy creditor claims totaling about $3.3 million for about $550,000 cash, expecting an approximate $2.75 million gain from debt extinguishment, subject to final accounting. Its board approved a 1-for-4 reverse stock split to support NYSE American minimum price compliance, reducing shares from ~25.2M to ~6.3M, effective July 27, 2026.

$SBEVMed

Splash Beverage Group Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation

Splash Beverage Group (NYSE American: SBEV) said NYSE American accepted its plan to regain continued listing compliance and granted a compliance period through Jan. 29, 2027, after the company submitted the plan on May 29, 2026. The company said it will execute strategic initiatives while maintaining its listing.

$SBEVMedAI 8/10

SPLASH BEVERAGE GROUP ACQUIRES EXCLUSIVE GLOBAL RIGHTS TO CANNEPIL®, AN EPILEPSY THERAPY WITH ESTABLISHED EUROPEAN PATIENT ACCESS, FDA ENGAGEMENT AND U.S. DEVELOPMENT POTENTIAL

Splash Beverage Group (NYSE American: SBEV) said it signed an exclusive global licensing deal with Argent BioPharma (ASX/LSE: RGT) for CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. CannEpil is approved for distribution in multiple countries and has initiated U.S. pre-IND/IND steps. Splash received a $1M investment commitment and will issue $5.5M preferred equity; Argent debt (~$5M) is forgiven. Argent earns a 15% net-revenue royalty.

$SBEVMed

Splash Beverage Group Secures Exclusive Global Rights To CannEpil For Drug- Resistant Epilepsy

Splash Beverage Group (SBEV) said it secured exclusive global licensing rights to CannEpil, a pharmaceutical-grade cannabinoid therapy for drug-resistant epilepsy, from Argent BioPharma (RGT.AX). CannEpil has patient access in Ireland, UK, Germany and Australia under EU-GMP, with Ireland MCAP reimbursement support and UK Named Patient Request import/prescription. SBEV cited pre-IND/IND progress for U.S. development.